Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: Insights into mechanism of assembly/disassembly from tissue factor

Matthew D. Stone, Stephen B. Harvey, Michael B. Martinez, Ronald R. Bach, Gary L. Nelsestuen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Active site-inhibited blood clotting factor VIIa (fVIIai) binds to tissue factor (TF), a cell surface receptor that is exposed upon injury and initiates the blood clotting cascade. FVIIai blocks binding of the corresponding enzyme (fVIIa) or zymogen (fVII) forms of factor VII and inhibits coagulation. Although several studies have suggested that fVIIai may have superior anticoagulation effects in vivo, a challenge for use of fVIIai is cost of production. This study reports the properties of dimeric forms of fVIIai that are cross-linked through their active sites. Dimeric wild-type fVIIai was at least 75-fold more effective than monomeric fVIIai in blocking fVIIa association with TF. The dimer of a mutant fVIIai with higher membrane affinity was 1600-fold more effective. Anticoagulation by any form of fVIIai differed substantially from agents such as heparin and showed a delayed mode of action. Coagulation proceeded normally for the first minutes, and inhibition increased as equilibrium binding was established. It is suggested that association of fVIIa(i) with TF in a collision-dependent reaction gives equal access of inhibitor and enzyme to TF. Assembly was not influenced by the higher affinity and slower dissociation of the dimer. As a result, anticoagulation was delayed until the reaction reached equilibrium. Properties of different dissociation experiments suggested that dissociation of fVIIai from TF occurred by a two-step mechanism. The first step was separation of TF-fVIIa(i) while both proteins remained bound to the membrane, and the second step was dissociation of the fVIIa(i) from the membrane. These results suggest novel actions of fVIIai that distinguish it from most of the anticoagulants that block later steps of the coagulation cascade.

Original languageEnglish (US)
Pages (from-to)6321-6330
Number of pages10
JournalBiochemistry
Volume44
Issue number16
DOIs
StatePublished - Apr 26 2005

Fingerprint

Protein Multimerization
Factor VIIa
Dimerization
Thromboplastin
Catalytic Domain
Coagulation
Proteins
Blood Coagulation
Membranes
Dimers
Blood
Association reactions
Enzyme Precursors
Factor VII
Blood Coagulation Factors
Cell Surface Receptors
Enzyme Inhibitors
Anticoagulants
Heparin
Costs and Cost Analysis

Cite this

Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization : Insights into mechanism of assembly/disassembly from tissue factor. / Stone, Matthew D.; Harvey, Stephen B.; Martinez, Michael B.; Bach, Ronald R.; Nelsestuen, Gary L.

In: Biochemistry, Vol. 44, No. 16, 26.04.2005, p. 6321-6330.

Research output: Contribution to journalArticle

@article{290a3f5d45c240caa67df27fdb8a5065,
title = "Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: Insights into mechanism of assembly/disassembly from tissue factor",
abstract = "Active site-inhibited blood clotting factor VIIa (fVIIai) binds to tissue factor (TF), a cell surface receptor that is exposed upon injury and initiates the blood clotting cascade. FVIIai blocks binding of the corresponding enzyme (fVIIa) or zymogen (fVII) forms of factor VII and inhibits coagulation. Although several studies have suggested that fVIIai may have superior anticoagulation effects in vivo, a challenge for use of fVIIai is cost of production. This study reports the properties of dimeric forms of fVIIai that are cross-linked through their active sites. Dimeric wild-type fVIIai was at least 75-fold more effective than monomeric fVIIai in blocking fVIIa association with TF. The dimer of a mutant fVIIai with higher membrane affinity was 1600-fold more effective. Anticoagulation by any form of fVIIai differed substantially from agents such as heparin and showed a delayed mode of action. Coagulation proceeded normally for the first minutes, and inhibition increased as equilibrium binding was established. It is suggested that association of fVIIa(i) with TF in a collision-dependent reaction gives equal access of inhibitor and enzyme to TF. Assembly was not influenced by the higher affinity and slower dissociation of the dimer. As a result, anticoagulation was delayed until the reaction reached equilibrium. Properties of different dissociation experiments suggested that dissociation of fVIIai from TF occurred by a two-step mechanism. The first step was separation of TF-fVIIa(i) while both proteins remained bound to the membrane, and the second step was dissociation of the fVIIa(i) from the membrane. These results suggest novel actions of fVIIai that distinguish it from most of the anticoagulants that block later steps of the coagulation cascade.",
author = "Stone, {Matthew D.} and Harvey, {Stephen B.} and Martinez, {Michael B.} and Bach, {Ronald R.} and Nelsestuen, {Gary L.}",
year = "2005",
month = "4",
day = "26",
doi = "10.1021/bi050007z",
language = "English (US)",
volume = "44",
pages = "6321--6330",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization

T2 - Insights into mechanism of assembly/disassembly from tissue factor

AU - Stone, Matthew D.

AU - Harvey, Stephen B.

AU - Martinez, Michael B.

AU - Bach, Ronald R.

AU - Nelsestuen, Gary L.

PY - 2005/4/26

Y1 - 2005/4/26

N2 - Active site-inhibited blood clotting factor VIIa (fVIIai) binds to tissue factor (TF), a cell surface receptor that is exposed upon injury and initiates the blood clotting cascade. FVIIai blocks binding of the corresponding enzyme (fVIIa) or zymogen (fVII) forms of factor VII and inhibits coagulation. Although several studies have suggested that fVIIai may have superior anticoagulation effects in vivo, a challenge for use of fVIIai is cost of production. This study reports the properties of dimeric forms of fVIIai that are cross-linked through their active sites. Dimeric wild-type fVIIai was at least 75-fold more effective than monomeric fVIIai in blocking fVIIa association with TF. The dimer of a mutant fVIIai with higher membrane affinity was 1600-fold more effective. Anticoagulation by any form of fVIIai differed substantially from agents such as heparin and showed a delayed mode of action. Coagulation proceeded normally for the first minutes, and inhibition increased as equilibrium binding was established. It is suggested that association of fVIIa(i) with TF in a collision-dependent reaction gives equal access of inhibitor and enzyme to TF. Assembly was not influenced by the higher affinity and slower dissociation of the dimer. As a result, anticoagulation was delayed until the reaction reached equilibrium. Properties of different dissociation experiments suggested that dissociation of fVIIai from TF occurred by a two-step mechanism. The first step was separation of TF-fVIIa(i) while both proteins remained bound to the membrane, and the second step was dissociation of the fVIIa(i) from the membrane. These results suggest novel actions of fVIIai that distinguish it from most of the anticoagulants that block later steps of the coagulation cascade.

AB - Active site-inhibited blood clotting factor VIIa (fVIIai) binds to tissue factor (TF), a cell surface receptor that is exposed upon injury and initiates the blood clotting cascade. FVIIai blocks binding of the corresponding enzyme (fVIIa) or zymogen (fVII) forms of factor VII and inhibits coagulation. Although several studies have suggested that fVIIai may have superior anticoagulation effects in vivo, a challenge for use of fVIIai is cost of production. This study reports the properties of dimeric forms of fVIIai that are cross-linked through their active sites. Dimeric wild-type fVIIai was at least 75-fold more effective than monomeric fVIIai in blocking fVIIa association with TF. The dimer of a mutant fVIIai with higher membrane affinity was 1600-fold more effective. Anticoagulation by any form of fVIIai differed substantially from agents such as heparin and showed a delayed mode of action. Coagulation proceeded normally for the first minutes, and inhibition increased as equilibrium binding was established. It is suggested that association of fVIIa(i) with TF in a collision-dependent reaction gives equal access of inhibitor and enzyme to TF. Assembly was not influenced by the higher affinity and slower dissociation of the dimer. As a result, anticoagulation was delayed until the reaction reached equilibrium. Properties of different dissociation experiments suggested that dissociation of fVIIai from TF occurred by a two-step mechanism. The first step was separation of TF-fVIIa(i) while both proteins remained bound to the membrane, and the second step was dissociation of the fVIIa(i) from the membrane. These results suggest novel actions of fVIIai that distinguish it from most of the anticoagulants that block later steps of the coagulation cascade.

UR - http://www.scopus.com/inward/record.url?scp=17644396668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644396668&partnerID=8YFLogxK

U2 - 10.1021/bi050007z

DO - 10.1021/bi050007z

M3 - Article

C2 - 15835921

AN - SCOPUS:17644396668

VL - 44

SP - 6321

EP - 6330

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 16

ER -